SX-682 (C007B-272748)

SX-682 is a potent, selective and orally bioavailable inhibitor of CXCR1/2 ,has the potential to treat castration-resistant prostate cancer.InformationSX-682 SX-682 is an orally bioavailable small-molecule allosteric inhibitor of CXCR1 and CXCR2 that blocks tumor MDSC recruitment and enhances T cell activation and antitumor immunity.TargetsCXCR1 ; CXCR2In vivoSX-682 significantly inhibited trafficking of PMN-MDSCs without altering CXCR2 ligand expression.?Trafficking of CXCR1+ macrophages was unaltered, possibly due to coexpression of CSF1R.?Reduced PMN-MDSC tumor infiltration correlated with enhanced accumulation of endogenous or adoptively transferred T cells.?Accordingly, tumor growth inhibition or the rate of established tumor rejection following programed death-axis (PD-axis) immune checkpoint blockade or adoptive cell transfer of engineered T cells was enhanced in combination with SX-682. Specification: 0.97 Molecular Formula: C19H14BF4N3O4S Molecular Weight: 467.2 PubChem CID: 90467234 Isomeric SMILES: B(C1=C(C=C(C=C1)OC(F)(F)F)CSC2=NC=C(C=N2)C(=O)NC3=CC=C(C=C3)F)(O)O Related Documents: https://ald-pub-files.oss-cn-shanghai.aliyuncs.com/aladdinsci/pdp/sds/1/S414287-SCI_c9f5c85f467a0c498b4c7bfc348a37e7.pdf